CA-DEXERIALS
Dexerials Corporation, (TOKYO: 4980) (Headquarters: Shimotsuke-shi, Tochigi, Representative Director and President: Yoshihisa Shinya, hereinafter “Dexerials”), which provides leading-edge technologies, materials, and devices for smartphones, automobiles, and other products, announces that the name of the integrated company to be created under Dexerials Precision Components Corporation (Headquarters: Tome-shi, Miyagi, Hereinafter “DXPC”) and Kyoto Semiconductor Co., Ltd. (Headquarters: Shimotsuke-shi, Tochigi, hereinafter “Kyoto Semiconductor”) has been determined as Dexerials Photonics Solutions Corporation (hereinafter “DXPS”), a consolidated subsidiary of Dexerials in Japan, and that DXPS will commence operation on April 1, 2024. In accordance with Dexerials’ news release on July 31, 2023, entitled Notice Regarding Launch of Integrated Company to Lead Growth in the Photonics Domain, preparations for a launch of the integrated company between DXPC and Kyoto Semiconductor had been made.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321222931/en/
Change in sales structure after the launch of DXPS (Graphic: Business Wire)
The profile of DXPS is as follows.
Profile of the integrated company
Corporate name |
Dexerials Photonics Solutions Corporation |
Head office |
Shimotsuke-shi, Tochigi |
Offices |
Eniwa Operation, Kamisunagawa Operation and Tome Operation |
Date of inauguration |
April 1, 2024 |
Share capital |
100 million yen |
Representative (planned) |
Kazuya Hayashibe, Representative Director and President |
Business |
Development, production and production management of optical semiconductors, optical devices and semiconductor-composite devices (photonics products) |
Dexerials Group will support DXPS in developing and providing solutions essential to the evolution of technologies in the photonics domain, aiming to increase efficiency in society. In so doing, the Group will help build a sustainable society, while aiming to achieve continuous growth and higher corporate value.
DXPS will develop and manufacture** microdevices and optical semiconductor device products that have been operated by DXPC and Kyoto Semiconductor. Dexerials will sell them to customers as its photonics products.
Dexerials and Kyoto Semiconductor will participate as an exhibitor at the OFC 2024 trade show that will take place at the San Diego Convention Center in San Diego in the United States from Tuesday, March 26 to Thursday, March 28. We cordially invite visitors to the exhibition to drop by our booth.
Comment from Kazuya Hayashibe, Representative Director and President (planned), DXPS
The Dexerials Group has been effectively combining technologies with the knowledge possessed by its human resources to offer materials and solutions indispensable to electronics and automobiles, aiming to link them to the evolution of digital technologies.
In the future, artificial intelligence (AI), Internet of things (IoT), next-generation communication and other new technologies will have increasing opportunities to play significant roles in boosting the efficiency of society for solving social issues. It is hence anticipated that optical semiconductors and the photonics solutions that support them will also have greater roles to play.
DXPS will lead the Dexerials Group’s business growth in the photonics domain. It will combine the optical semiconductor technologies cultivated by Kyoto Semiconductor, one of its predecessors, with the Dexerials Group’s technologies of controlling light and electricity to create unprecedented photonics solutions and to help resolve social issues. This will be the reason for its existence and it will tackle its work with a strong determination.
Dexerials and Kyoto Semiconductor will showcase their products and present the integrated company, DXPS, in their booth at the OFC 2024 exhibition that will start on March 26 in San Diego in the United States. We cordially invite visitors to the exhibition to drop by our booth. We look forward to seeing you at San Diego.
Change in sales structure after the launch of DXPS
Please see the diagram.
(Notes) |
* DXPC, Kyoto Semiconductor and DXPS are wholly owned subsidiaries of Dexerials Corporation. |
|
** After the launch of DXPS, OSDC will continue to manufacture microdevices under contract. |
|
*** Photonics products correspond to products that have been handled by DXPC and Kyoto Semiconductor. |
Participation in the OFC 2024 exhibition in San Diego, USA
OFC 2024 Exhibition
Date: Tuesday, March 26, 2024 to Thursday, March 28, 2024
Venue: San Diego Convention Center (San Diego, USA)
Stand number: 3814
Official website: https://www.ofcconference.org/en-us/home/
Products to be displayed
1. Optical semiconductor
2. Inorganic waveplate
3. Smart precision Adhesive
4. Anisotropic Conductive Film (ACF)
About Dexerials Corporation https://www.dexerials.jp/en/
Dexerials Corporation is a manufacturer providing functional materials for use in smartphones, automobiles and other domains in accordance with its corporate vision, Value Matters - Unprecedented innovation, unprecedented value. On a global scale, Dexerials Corporation manufactures and markets Anisotropic Conductive Film (ACF), optical elastic resin (SVR), anti-reflection film, surface mounted type fuses, industrial adhesives, double- and single-sided tapes and other electronic parts, junction materials, optical materials, and many other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321222931/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom